By Bret Coons
Northwestern’s Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery. The heart valve under study, the Direct Flow Medical® Transcathether Aortic Valve System manufactured by Direct Flow Medical, Inc., is a non-metallic, investigational device specifically designed to be placed inside the heart using a catheter that is inserted through a blood vessel in the groin and then navigated into the aorta to the heart. The study valve is also designed to have the unique ability to be repositioned or even replaced with a different size after the valve’s initial placement to achieve a better fit if one is needed.
By Todd Medland
July is a very significant month for Susan Fischer and her family. Her son is getting married and her daughter is expecting her second child. While Fischer can’t wait for all of the excitement to unfold, she has a number of restrictions to deal with on a daily basis. She has severe emphysema, also known as chronic obstructive pulmonary disease (COPD), which is an ongoing and progressive disease that damages the lungs and makes breathing difficult. Fischer was determined to not let her condition slow her down during these important family milestones.
By Todd Medland
November is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death for both men and women in the United States. It has a five-year survival rate of only 15 percent. Often, lung cancers grow silently for many years and reach an advanced stage before causing symptoms that lead to diagnosis and treatment. But, there is some good news. Research from the National Cancer Institute’s National Lung Screening Trial (NLST), found that screening with low dose computed tomography (CT) reduces lung cancer mortality by 20 percent. The NLST findings have led to widespread use of low dose CT scans for lung cancer screening, including at Northwestern Memorial Hospital.
By Todd Medland
Lung cancer is the leading cause of cancer death for both men and women in the United States. It has a five-year survival rate of only 15 percent. Research from the National Cancer Institute’s National Lung Cancer Screening Trial (NLST), found that low-dose computed tomography (CT) is a promising test for the detection of pre-symptomatic lung cancer in individuals with the highest risk for lung cancer. The trial found that using CT screening reduced deaths by 20 percent compared to the chest X-ray. The NLST findings have led to widespread use of CT scans for lung cancer screening. Based on the NLST findings, the American Lung Association recommends lung cancer screening with low-dose CT scans for people who meet a certain criteria, including:
About this Blog
The Northwestern Medicine News Blog features health system news, research innovations, health information and various perspectives—including clinical and medical information as well as other healthcare-related issues.